Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
West Virginia University Charleston Division
mi
from
Charleston, WV
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
West Virginia University Charleston Division
mi
from
Charleston, WV
Click here to add this to my saved trials
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Click here to add this to my saved trials
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Oncology Group
mi
from
Philadelphia, PA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Hospital for Sick Children
mi
from
Toronto,
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Baptist Cancer Institute
mi
from
Jacksonville, FL
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Orlando Health
mi
from
Orlando, FL
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute
mi
from
Atlanta, GA
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
DUMC
mi
from
Durham, NC
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
DUMC
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Duke University Hospital
mi
from
Durham, NC
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
University Hospitals
mi
from
Cleveland, OH
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Status: Enrolling
Updated:  12/31/1969
Lineberger Comprehensive Cancer Center, University of North Carolina
mi
from
Chapel Hill, NC
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Status: Enrolling
Updated: 12/31/1969
Lineberger Comprehensive Cancer Center, University of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Gilbert, AZ
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Hot Springs, AR
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Encinitas, CA
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
La Jolla, CA
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
La Jolla, CA
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Long Beach, CA
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Los Angeles, CA
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Local Institution
mi
from
Denver, CO
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Local Institution
mi
from
Denver, CO
Click here to add this to my saved trials